Compare Davita Inc (DVA) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs VanEck Gold Miners ETF — how do they compare? Davita Inc trades at $231.65 (market cap $14.92B), while VanEck Gold Miners ETF trades at $74.1. The key difference: Davita Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| DVA | GDX | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | — |
52-Week High | $235.71 | $115.84 |
52-Week Low | $103.87 | $51.15 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GDX, the VanEck Gold Miners ETF, trades at $73.37, down 2.86% in the last 24 hours amid a bearish technical signal from moving averages. The fund's valuation metrics are not available, but recent news highlights competition from lower-fee gold ETFs and a recent addition of Aya Gold & Silver to its holdings. Technical indicators show neutral oscillators with key support at $71 and resistance at $74.
The outlook for GDX is cautious due to underperformance versus physical gold and higher volatility. Investment opportunities lie in potential gold price rebounds and record-high free cash flow yields, but risks include fee disadvantages and sector-specific volatility. Analyst sentiment is mixed, with some seeing a buying opportunity amid low valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
